- MaxCyte said it had expanded its relationship with Kite, a Gilead company, by entering into a multi-drug clinical and commercial agreement.

Under the terms of the agreement, Kite would use MaxCyte's flow electroporation technology to enable non-viral cell engineering for development of up to 10 drug targets.

Kite would obtain non-exclusive clinical and commercial-use rights to MaxCyte's cell engineering platform, while MaxCyte would receive development and approval milestones and sales-based payments in addition to other licensing fees.

The expansion of the relationship built on an existing research agreement announced in November 2018

At 8:32am: [LON:MXCT] MaxCyte Inc share price was 0p at 177.5p

Story provided by